AbbVie subsidiary Allergan will pay about US$30 million to resolve the remainder of a consolidated antitrust class action over its alleged scheme to delay generic versions of the dry-eye treatment Restasis, according to a federal court filing in Brooklyn.
The insurers and pension funds leading part of the lawsuit sought preliminary approval from Judge Nina Gershon for the US$29,999,999.99 settlement on behalf of “end payers” that completely or partially covered consumer sales of the drug.
The October 8 request comes about four months after Gershon paused the case while the two sides hammered out a final deal.
The proposed class action settlement was disclosed in a filing on Tuesday, October 12, in federal court in Brooklyn and would resolve claims by direct purchasers of Restasis such as wholesalers who claimed that Allergan’s actions led them to be overcharged for the drug.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
